Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

Core Viewpoint - Can-Fite BioPharma Ltd. has announced promising results for its lead drug candidate, namodenoson, in treating obesity, supported by a peer-reviewed study demonstrating its anti-obesity effects and favorable safety profile [1][4][6]. Group 1: Study Findings - The study published in the International Journal of Obesity shows that namodenoson significantly inhibits adipocyte proliferation and lipid droplet accumulation in a dose-dependent manner [4]. - In a murine high-fat diet model, daily oral administration of namodenoson for four weeks resulted in a statistically significant reduction in weight gain compared to placebo-treated controls [4]. - The findings align with previous Phase IIa clinical study results, where namodenoson treatment for three months led to reductions in liver fat and body weight in patients with metabolic dysfunction-associated steatohepatitis (MASH) [3][4]. Group 2: Mechanism of Action - Namodenoson modulates key molecular pathways involved in adipogenesis and inflammation, upregulating adiponectin and suppressing various signaling pathways such as PI3K, NF-κB, Akt, and Wnt/β-catenin [5]. - The drug's mechanism suggests a multi-pathway metabolic approach to obesity treatment [5]. Group 3: Market Potential - The global obesity treatment market is projected to reach $60.5 billion by 2030, with a compound annual growth rate (CAGR) of approximately 22%, driven by increasing disease prevalence and demand for safe, effective oral therapies [7]. - Namodenoson's favorable safety profile and broad patent portfolio position it as a promising candidate in this rapidly growing market [4][6]. Group 4: Company Overview - Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][9]. - Namodenoson is currently in advanced clinical development for MASH and is also being evaluated in pivotal trials for advanced liver cancer and pancreatic cancer [8][10].